Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.620
-0.050 (-2.99%)
Apr 7, 2026, 1:07 PM EDT - Market open
Coherus Oncology Revenue
In the year 2025, Coherus Oncology had annual revenue of $42.17M with 59.81% growth. Coherus Oncology had revenue of $12.75M in the quarter ending December 31, 2025, with 64.85% growth.
Revenue (ttm)
$42.17M
Revenue Growth
+59.81%
P/S Ratio
5.94
Revenue / Employee
$286,884
Employees
147
Market Cap
242.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.17M | 15.78M | 59.81% |
| Dec 31, 2024 | 26.39M | -230.86M | -89.74% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | 356.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
| Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
| Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
| Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
| Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
| Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Cellectis | 79.59M |
| Editas Medicine | 40.52M |
| Voyager Therapeutics | 40.37M |
| Orchestra BioMed Holdings | 33.48M |
| Alector | 21.05M |
| Sol-Gel Technologies | 19.39M |
CHRS News
- 4 weeks ago - Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewsWire
- 6 weeks ago - Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) - GlobeNewsWire
- 4 months ago - Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - GlobeNewsWire